Occam Places Aron Feingold as VP of Investor Relations & Corporate Communications at Geron
_410x328.avif)
Geron is a public, clinical stage biotech company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies.
In early 2022, Occam placed Aron Feingold (former Sangamo and Pfizer), as VP of Investor Relations & Corporate Communications, a role crucial to Geron at this point in its evolution, as it approaches potential registration and commercialization.
Read more about Occam's work with Geron in our case study.
Related Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.